CSL Behringsp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-09-19
Share capital
5,000.00 PLN
Average employment (FTE)
24 (2025)
Registered address
Branickiego 17, 02-972 Warszawa, Poland
Website
cslbehring.com
Social media
Electronic delivery address
AE:PL-70775-64300-CETRA-23

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$885,809
Profit allocationRetained in reserve capital
Loans and borrowings$15,461,391
Foreign sales94.03% of revenue ($82,175,324)
Revenue structuresprzedaż produktów
Receivables write-downs$418,356

Filing timeliness

Financial statements were filed on time, on average 55 days early. All were audited by a statutory auditor.

  • 202503/12/2025
  • 202405/11/2024
  • 202320/10/2023
  • 202221/12/2022
  • 202101/12/2021
  • 202016/02/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods80 / 1,141
Top 7.0%
Division · Wholesale trade390 / 19,988
Top 1.9%
Sector · Wholesale and retail trade; repair of motor vehicles including motorcycles527 / 29,903
Top 1.8%
City · Warszawa751 / 56,967
Top 1.3%
Voivodeship · Mazowieckie974 / 77,130
Top 1.3%
Country · Poland2,766 / 297,932
Top <1%

Results vs industry

Revenue
This companyUSD 82.57mMedianUSD 1.07mAverageUSD 22.39m
Net profit
This companyUSD 3.47mMedianUSD 37.46kAverageUSD 877.59k
Operating costs
This companyUSD 77.47mMedianUSD 932.14kAverageUSD 21.07m
Assets
This companyUSD 36.50mMedianUSD 609.79kAverageUSD 11.84m

Industry

Public procurement

379 tenders recorded as contractor: 50 national ($3,631,799) and 329 EU ($701,237,903).

SubjectAmount
Successive supply of Immunoglobulin Hyumanum.
$816.9K
Coagulation factor XIII concentrate with delivery to Regional Blood Donation and Blood Treatment Centres; procedure reference: ZZP.ZP.411.118.2026
$106.8K
Recombinant coagulation factor IX concentrate, minimum second generation, including delivery to Regional Blood Donation and Blood Treatment Centers; procedure reference: ZZP.ZP.411.117.2026, lots 1–3
$401.8K

Authorized Representatives

Beata Marzena Szymańska-Czyż – Attorney-in-fact (joint)
Dariusz Hołdys – Attorney-in-fact (joint)
Grażyna Dębowska – Attorney-in-fact (joint)
Tomasz Robert Górski – Attorney-in-fact (joint)
Marek Janusz Skotnickiage 61 – Management Board Member

Manner of representation

The following persons are authorized to represent the company and to make declarations of will on its behalf: two members of the management board acting jointly, or one member of the management board acting with a commercial proxy.

Ownership

OwnerSharesShare valueStake
Csl Behring Aps
100$1,350.62100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2011-09-27.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 5,112

Secured liabilities

Type
Registered pledge

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Ipsen Polandsp. z o.o.
Intervetsp. z o.o.
Magnapharm Polandsp. z o.o.
Chiesi Polandsp. z o.o.
Pierre Fabre Medicament Polska .sp. z o.o.
Perrigo Polandsp. z o.o.
Aurovitas Pharma Polskasp. z o.o.
Kol-Dentalsp. z o.o. + limited partnership
Alfasigma Polskasp. z o.o.
Baxter Polskasp. z o.o.

Change history

DateEvent
2012-12-18Address change
2012-06-04Name change
2012-06-04PKD change
2011-09-19Entered in the register

FAQ

Last updated: 2026-10-07